Skip to search formSkip to main contentSkip to account menu

MVA-MUC1-IL2 Vaccine

Known as: MVA-MUC1-IL2, Modified Vaccinia Ankara Encoding Human MUC-1 Antigen and Interleukin-2 Suspension 
A bivalent cancer vaccine comprised of a modified vaccinia virus Ankara (MVA) strain encoding human mucin 1 (MUC1) and interleukin-2 (IL-2) with… 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (2)

MVA-MUC1-IL2™TG4010

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Randomized phase IIb trial evaluating the therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
8023 Background: TG4010 is a recombinant Modified Virus Ankara (MVA) expressing both IL2 and the tumor-associated antigen MUC1… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)